FCM
CRL icon

Fortis Capital Management’s Charles River Laboratories CRL Stock Holding History

Fortis Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,000
Closed -$1.65M – 123
2023
Q4 		$1.65M Hold
7,000
– – 0.42% 53
2023
Q3 		$1.37M Buy
+7,000
New +$1.44M 0.43% 50

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Fortis Capital Management's CRL Position: Q1 2024 in Review

Fortis Capital Management sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 7,000 shares — an estimated $1.65M sold.

Fortis Capital Management first reported a position in CRL in Q3 2023 and held it in 2 quarters. The position peaked at $1.65M in Q4 2023. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

  • Fortis Capital Management reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
  • Fortis Capital Management sold 7,000 Charles River Laboratories shares in Q1 2024, an estimated $1.65M.
  • Fortis Capital Management first reported a position in Charles River Laboratories in Q3 2023 and held it in 2 quarters.
  • Fortis Capital Management's Charles River Laboratories position peaked at $1.65M in Q4 2023.
  • 676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Fortis Capital Management's 13F filing for Q1 2024, filed 30 Apr 2024.